nodes	percent_of_prediction	percent_of_DWPC	metapath
Salmeterol—CYP3A7—Ifosfamide—hematologic cancer	0.0294	0.0426	CbGbCtD
Salmeterol—CYP3A7-CYP3A51P—Ifosfamide—hematologic cancer	0.0294	0.0426	CbGbCtD
Salmeterol—CYP3A7—Imatinib—hematologic cancer	0.0281	0.0407	CbGbCtD
Salmeterol—CYP3A7-CYP3A51P—Imatinib—hematologic cancer	0.0281	0.0407	CbGbCtD
Salmeterol—CYP2C8—Bortezomib—hematologic cancer	0.0277	0.04	CbGbCtD
Salmeterol—CYP3A5—Daunorubicin—hematologic cancer	0.0275	0.0398	CbGbCtD
Salmeterol—CYP3A5—Thalidomide—hematologic cancer	0.0251	0.0363	CbGbCtD
Salmeterol—CYP3A5—Teniposide—hematologic cancer	0.0239	0.0346	CbGbCtD
Salmeterol—CYP3A5—Ifosfamide—hematologic cancer	0.0221	0.0319	CbGbCtD
Salmeterol—CYP2C8—Ifosfamide—hematologic cancer	0.0212	0.0307	CbGbCtD
Salmeterol—CYP3A5—Imatinib—hematologic cancer	0.0211	0.0305	CbGbCtD
Salmeterol—CYP2C8—Nilotinib—hematologic cancer	0.0184	0.0267	CbGbCtD
Salmeterol—CYP3A4—Bexarotene—hematologic cancer	0.0183	0.0265	CbGbCtD
Salmeterol—CYP3A7—Irinotecan—hematologic cancer	0.0176	0.0254	CbGbCtD
Salmeterol—CYP3A7-CYP3A51P—Irinotecan—hematologic cancer	0.0176	0.0254	CbGbCtD
Salmeterol—CYP3A4—Busulfan—hematologic cancer	0.017	0.0246	CbGbCtD
Salmeterol—CYP3A4—Lomustine—hematologic cancer	0.017	0.0246	CbGbCtD
Salmeterol—CYP3A5—Dasatinib—hematologic cancer	0.0169	0.0245	CbGbCtD
Salmeterol—CYP3A7-CYP3A51P—Vincristine—hematologic cancer	0.0153	0.0222	CbGbCtD
Salmeterol—CYP3A7—Vincristine—hematologic cancer	0.0153	0.0222	CbGbCtD
Salmeterol—CYP3A4—Thiotepa—hematologic cancer	0.0152	0.022	CbGbCtD
Salmeterol—CYP3A5—Irinotecan—hematologic cancer	0.0132	0.0191	CbGbCtD
Salmeterol—CYP3A4—Methoxsalen—hematologic cancer	0.0118	0.0171	CbGbCtD
Salmeterol—CYP3A7—Dexamethasone—hematologic cancer	0.0116	0.0167	CbGbCtD
Salmeterol—CYP3A7-CYP3A51P—Dexamethasone—hematologic cancer	0.0116	0.0167	CbGbCtD
Salmeterol—CYP3A5—Vincristine—hematologic cancer	0.0115	0.0167	CbGbCtD
Salmeterol—CYP3A4—Bortezomib—hematologic cancer	0.0112	0.0162	CbGbCtD
Salmeterol—CYP3A4—Daunorubicin—hematologic cancer	0.0107	0.0155	CbGbCtD
Salmeterol—CYP3A5—Etoposide—hematologic cancer	0.0105	0.0153	CbGbCtD
Salmeterol—CYP2C8—Etoposide—hematologic cancer	0.0101	0.0147	CbGbCtD
Salmeterol—CYP3A4—Cytarabine—hematologic cancer	0.00947	0.0137	CbGbCtD
Salmeterol—CYP3A4—Teniposide—hematologic cancer	0.00933	0.0135	CbGbCtD
Salmeterol—CYP3A5—Dexamethasone—hematologic cancer	0.00867	0.0125	CbGbCtD
Salmeterol—CYP3A4—Ifosfamide—hematologic cancer	0.00861	0.0125	CbGbCtD
Salmeterol—CYP2C8—Dexamethasone—hematologic cancer	0.00834	0.0121	CbGbCtD
Salmeterol—CYP3A4—Imatinib—hematologic cancer	0.00822	0.0119	CbGbCtD
Salmeterol—CYP3A4—Ruxolitinib—hematologic cancer	0.00774	0.0112	CbGbCtD
Salmeterol—CYP3A4—Nilotinib—hematologic cancer	0.00747	0.0108	CbGbCtD
Salmeterol—CYP3A4—Vinorelbine—hematologic cancer	0.00741	0.0107	CbGbCtD
Salmeterol—CYP3A4—Triamcinolone—hematologic cancer	0.00678	0.0098	CbGbCtD
Salmeterol—CYP3A4—Dasatinib—hematologic cancer	0.0066	0.00955	CbGbCtD
Salmeterol—CYP3A4—Mitoxantrone—hematologic cancer	0.00652	0.00944	CbGbCtD
Salmeterol—CYP3A4—Betamethasone—hematologic cancer	0.00581	0.00841	CbGbCtD
Salmeterol—CYP3A4—Prednisolone—hematologic cancer	0.00574	0.0083	CbGbCtD
Salmeterol—CYP3A4—Prednisone—hematologic cancer	0.00542	0.00784	CbGbCtD
Salmeterol—CYP3A4—Irinotecan—hematologic cancer	0.00514	0.00743	CbGbCtD
Salmeterol—CYP3A4—Vinblastine—hematologic cancer	0.00457	0.00661	CbGbCtD
Salmeterol—CYP3A4—Vincristine—hematologic cancer	0.00449	0.00649	CbGbCtD
Salmeterol—CYP3A4—Etoposide—hematologic cancer	0.00411	0.00595	CbGbCtD
Salmeterol—CYP3A4—Dexamethasone—hematologic cancer	0.00338	0.00489	CbGbCtD
Salmeterol—CYP3A4—Doxorubicin—hematologic cancer	0.00281	0.00406	CbGbCtD
Salmeterol—Nausea—Ifosfamide—hematologic cancer	4.18e-05	0.000136	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Betamethasone—hematologic cancer	4.16e-05	0.000136	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	4.16e-05	0.000136	CcSEcCtD
Salmeterol—Arthralgia—Prednisone—hematologic cancer	4.15e-05	0.000135	CcSEcCtD
Salmeterol—Myalgia—Prednisone—hematologic cancer	4.15e-05	0.000135	CcSEcCtD
Salmeterol—Feeling abnormal—Triamcinolone—hematologic cancer	4.15e-05	0.000135	CcSEcCtD
Salmeterol—Diarrhoea—Cisplatin—hematologic cancer	4.15e-05	0.000135	CcSEcCtD
Salmeterol—Anxiety—Prednisone—hematologic cancer	4.14e-05	0.000135	CcSEcCtD
Salmeterol—Vomiting—Gemcitabine—hematologic cancer	4.13e-05	0.000135	CcSEcCtD
Salmeterol—Insomnia—Betamethasone—hematologic cancer	4.13e-05	0.000135	CcSEcCtD
Salmeterol—Insomnia—Dexamethasone—hematologic cancer	4.13e-05	0.000135	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	4.12e-05	0.000134	CcSEcCtD
Salmeterol—Paraesthesia—Dexamethasone—hematologic cancer	4.1e-05	0.000134	CcSEcCtD
Salmeterol—Paraesthesia—Betamethasone—hematologic cancer	4.1e-05	0.000134	CcSEcCtD
Salmeterol—Discomfort—Prednisone—hematologic cancer	4.1e-05	0.000134	CcSEcCtD
Salmeterol—Mental disorder—Methotrexate—hematologic cancer	4.1e-05	0.000134	CcSEcCtD
Salmeterol—Rash—Gemcitabine—hematologic cancer	4.1e-05	0.000134	CcSEcCtD
Salmeterol—Dermatitis—Gemcitabine—hematologic cancer	4.1e-05	0.000134	CcSEcCtD
Salmeterol—Hypersensitivity—Etoposide—hematologic cancer	4.09e-05	0.000133	CcSEcCtD
Salmeterol—Malnutrition—Methotrexate—hematologic cancer	4.07e-05	0.000133	CcSEcCtD
Salmeterol—Headache—Gemcitabine—hematologic cancer	4.07e-05	0.000133	CcSEcCtD
Salmeterol—Nausea—Vincristine—hematologic cancer	4.07e-05	0.000133	CcSEcCtD
Salmeterol—Cardiac disorder—Epirubicin—hematologic cancer	4.07e-05	0.000133	CcSEcCtD
Salmeterol—Rhinitis—Doxorubicin—hematologic cancer	4.06e-05	0.000133	CcSEcCtD
Salmeterol—Hypersensitivity—Prednisolone—hematologic cancer	4.03e-05	0.000132	CcSEcCtD
Salmeterol—Pharyngitis—Doxorubicin—hematologic cancer	4.02e-05	0.000131	CcSEcCtD
Salmeterol—Dyspepsia—Betamethasone—hematologic cancer	4.02e-05	0.000131	CcSEcCtD
Salmeterol—Dyspepsia—Dexamethasone—hematologic cancer	4.02e-05	0.000131	CcSEcCtD
Salmeterol—Urticaria—Triamcinolone—hematologic cancer	4e-05	0.00013	CcSEcCtD
Salmeterol—Asthenia—Etoposide—hematologic cancer	3.98e-05	0.00013	CcSEcCtD
Salmeterol—Connective tissue disorder—Doxorubicin—hematologic cancer	3.98e-05	0.00013	CcSEcCtD
Salmeterol—Body temperature increased—Triamcinolone—hematologic cancer	3.98e-05	0.00013	CcSEcCtD
Salmeterol—Anaphylactic shock—Prednisone—hematologic cancer	3.98e-05	0.00013	CcSEcCtD
Salmeterol—Oedema—Prednisone—hematologic cancer	3.98e-05	0.00013	CcSEcCtD
Salmeterol—Nausea—Mitoxantrone—hematologic cancer	3.96e-05	0.000129	CcSEcCtD
Salmeterol—Nausea—Irinotecan—hematologic cancer	3.96e-05	0.000129	CcSEcCtD
Salmeterol—Immune system disorder—Epirubicin—hematologic cancer	3.96e-05	0.000129	CcSEcCtD
Salmeterol—Infection—Prednisone—hematologic cancer	3.95e-05	0.000129	CcSEcCtD
Salmeterol—Mediastinal disorder—Epirubicin—hematologic cancer	3.95e-05	0.000129	CcSEcCtD
Salmeterol—Back pain—Methotrexate—hematologic cancer	3.94e-05	0.000129	CcSEcCtD
Salmeterol—Fatigue—Dexamethasone—hematologic cancer	3.94e-05	0.000128	CcSEcCtD
Salmeterol—Fatigue—Betamethasone—hematologic cancer	3.94e-05	0.000128	CcSEcCtD
Salmeterol—Arrhythmia—Epirubicin—hematologic cancer	3.91e-05	0.000128	CcSEcCtD
Salmeterol—Pain—Betamethasone—hematologic cancer	3.91e-05	0.000127	CcSEcCtD
Salmeterol—Pain—Dexamethasone—hematologic cancer	3.91e-05	0.000127	CcSEcCtD
Salmeterol—Nervous system disorder—Prednisone—hematologic cancer	3.9e-05	0.000127	CcSEcCtD
Salmeterol—Tachycardia—Prednisone—hematologic cancer	3.88e-05	0.000127	CcSEcCtD
Salmeterol—Skin disorder—Prednisone—hematologic cancer	3.86e-05	0.000126	CcSEcCtD
Salmeterol—Nausea—Gemcitabine—hematologic cancer	3.86e-05	0.000126	CcSEcCtD
Salmeterol—Vomiting—Cisplatin—hematologic cancer	3.85e-05	0.000126	CcSEcCtD
Salmeterol—Mental disorder—Epirubicin—hematologic cancer	3.84e-05	0.000125	CcSEcCtD
Salmeterol—Rash—Cisplatin—hematologic cancer	3.82e-05	0.000125	CcSEcCtD
Salmeterol—Dermatitis—Cisplatin—hematologic cancer	3.82e-05	0.000125	CcSEcCtD
Salmeterol—Malnutrition—Epirubicin—hematologic cancer	3.81e-05	0.000124	CcSEcCtD
Salmeterol—Diarrhoea—Etoposide—hematologic cancer	3.8e-05	0.000124	CcSEcCtD
Salmeterol—Ill-defined disorder—Methotrexate—hematologic cancer	3.78e-05	0.000123	CcSEcCtD
Salmeterol—Feeling abnormal—Dexamethasone—hematologic cancer	3.77e-05	0.000123	CcSEcCtD
Salmeterol—Feeling abnormal—Betamethasone—hematologic cancer	3.77e-05	0.000123	CcSEcCtD
Salmeterol—Cardiac disorder—Doxorubicin—hematologic cancer	3.76e-05	0.000123	CcSEcCtD
Salmeterol—Tension—Epirubicin—hematologic cancer	3.74e-05	0.000122	CcSEcCtD
Salmeterol—Gastrointestinal pain—Dexamethasone—hematologic cancer	3.74e-05	0.000122	CcSEcCtD
Salmeterol—Gastrointestinal pain—Betamethasone—hematologic cancer	3.74e-05	0.000122	CcSEcCtD
Salmeterol—Hypersensitivity—Triamcinolone—hematologic cancer	3.71e-05	0.000121	CcSEcCtD
Salmeterol—Nervousness—Epirubicin—hematologic cancer	3.7e-05	0.000121	CcSEcCtD
Salmeterol—Back pain—Epirubicin—hematologic cancer	3.69e-05	0.00012	CcSEcCtD
Salmeterol—Malaise—Methotrexate—hematologic cancer	3.67e-05	0.00012	CcSEcCtD
Salmeterol—Dizziness—Etoposide—hematologic cancer	3.67e-05	0.00012	CcSEcCtD
Salmeterol—Muscle spasms—Epirubicin—hematologic cancer	3.67e-05	0.00012	CcSEcCtD
Salmeterol—Immune system disorder—Doxorubicin—hematologic cancer	3.66e-05	0.000119	CcSEcCtD
Salmeterol—Mediastinal disorder—Doxorubicin—hematologic cancer	3.65e-05	0.000119	CcSEcCtD
Salmeterol—Urticaria—Betamethasone—hematologic cancer	3.63e-05	0.000118	CcSEcCtD
Salmeterol—Urticaria—Dexamethasone—hematologic cancer	3.63e-05	0.000118	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Prednisone—hematologic cancer	3.63e-05	0.000118	CcSEcCtD
Salmeterol—Dizziness—Prednisolone—hematologic cancer	3.62e-05	0.000118	CcSEcCtD
Salmeterol—Arrhythmia—Doxorubicin—hematologic cancer	3.62e-05	0.000118	CcSEcCtD
Salmeterol—Asthenia—Triamcinolone—hematologic cancer	3.61e-05	0.000118	CcSEcCtD
Salmeterol—Abdominal pain—Dexamethasone—hematologic cancer	3.61e-05	0.000118	CcSEcCtD
Salmeterol—Body temperature increased—Dexamethasone—hematologic cancer	3.61e-05	0.000118	CcSEcCtD
Salmeterol—Abdominal pain—Betamethasone—hematologic cancer	3.61e-05	0.000118	CcSEcCtD
Salmeterol—Body temperature increased—Betamethasone—hematologic cancer	3.61e-05	0.000118	CcSEcCtD
Salmeterol—Nausea—Cisplatin—hematologic cancer	3.6e-05	0.000117	CcSEcCtD
Salmeterol—Insomnia—Prednisone—hematologic cancer	3.6e-05	0.000117	CcSEcCtD
Salmeterol—Paraesthesia—Prednisone—hematologic cancer	3.57e-05	0.000117	CcSEcCtD
Salmeterol—Cough—Methotrexate—hematologic cancer	3.56e-05	0.000116	CcSEcCtD
Salmeterol—Mental disorder—Doxorubicin—hematologic cancer	3.55e-05	0.000116	CcSEcCtD
Salmeterol—Ill-defined disorder—Epirubicin—hematologic cancer	3.54e-05	0.000115	CcSEcCtD
Salmeterol—Vomiting—Etoposide—hematologic cancer	3.53e-05	0.000115	CcSEcCtD
Salmeterol—Malnutrition—Doxorubicin—hematologic cancer	3.53e-05	0.000115	CcSEcCtD
Salmeterol—Agitation—Epirubicin—hematologic cancer	3.5e-05	0.000114	CcSEcCtD
Salmeterol—Dyspepsia—Prednisone—hematologic cancer	3.5e-05	0.000114	CcSEcCtD
Salmeterol—Rash—Etoposide—hematologic cancer	3.5e-05	0.000114	CcSEcCtD
Salmeterol—Dermatitis—Etoposide—hematologic cancer	3.5e-05	0.000114	CcSEcCtD
Salmeterol—Headache—Etoposide—hematologic cancer	3.48e-05	0.000113	CcSEcCtD
Salmeterol—Arthralgia—Methotrexate—hematologic cancer	3.47e-05	0.000113	CcSEcCtD
Salmeterol—Myalgia—Methotrexate—hematologic cancer	3.47e-05	0.000113	CcSEcCtD
Salmeterol—Chest pain—Methotrexate—hematologic cancer	3.47e-05	0.000113	CcSEcCtD
Salmeterol—Tension—Doxorubicin—hematologic cancer	3.46e-05	0.000113	CcSEcCtD
Salmeterol—Rash—Prednisolone—hematologic cancer	3.45e-05	0.000113	CcSEcCtD
Salmeterol—Dermatitis—Prednisolone—hematologic cancer	3.45e-05	0.000113	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	3.45e-05	0.000112	CcSEcCtD
Salmeterol—Malaise—Epirubicin—hematologic cancer	3.44e-05	0.000112	CcSEcCtD
Salmeterol—Fatigue—Prednisone—hematologic cancer	3.43e-05	0.000112	CcSEcCtD
Salmeterol—Headache—Prednisolone—hematologic cancer	3.43e-05	0.000112	CcSEcCtD
Salmeterol—Discomfort—Methotrexate—hematologic cancer	3.43e-05	0.000112	CcSEcCtD
Salmeterol—Nervousness—Doxorubicin—hematologic cancer	3.43e-05	0.000112	CcSEcCtD
Salmeterol—Back pain—Doxorubicin—hematologic cancer	3.41e-05	0.000111	CcSEcCtD
Salmeterol—Constipation—Prednisone—hematologic cancer	3.4e-05	0.000111	CcSEcCtD
Salmeterol—Muscle spasms—Doxorubicin—hematologic cancer	3.39e-05	0.000111	CcSEcCtD
Salmeterol—Palpitations—Epirubicin—hematologic cancer	3.37e-05	0.00011	CcSEcCtD
Salmeterol—Dizziness—Triamcinolone—hematologic cancer	3.33e-05	0.000109	CcSEcCtD
Salmeterol—Cough—Epirubicin—hematologic cancer	3.33e-05	0.000109	CcSEcCtD
Salmeterol—Anaphylactic shock—Methotrexate—hematologic cancer	3.33e-05	0.000108	CcSEcCtD
Salmeterol—Infection—Methotrexate—hematologic cancer	3.3e-05	0.000108	CcSEcCtD
Salmeterol—Nausea—Etoposide—hematologic cancer	3.3e-05	0.000108	CcSEcCtD
Salmeterol—Hypertension—Epirubicin—hematologic cancer	3.29e-05	0.000107	CcSEcCtD
Salmeterol—Feeling abnormal—Prednisone—hematologic cancer	3.28e-05	0.000107	CcSEcCtD
Salmeterol—Asthenia—Betamethasone—hematologic cancer	3.28e-05	0.000107	CcSEcCtD
Salmeterol—Asthenia—Dexamethasone—hematologic cancer	3.28e-05	0.000107	CcSEcCtD
Salmeterol—Ill-defined disorder—Doxorubicin—hematologic cancer	3.27e-05	0.000107	CcSEcCtD
Salmeterol—Nervous system disorder—Methotrexate—hematologic cancer	3.26e-05	0.000106	CcSEcCtD
Salmeterol—Gastrointestinal pain—Prednisone—hematologic cancer	3.25e-05	0.000106	CcSEcCtD
Salmeterol—Nausea—Prednisolone—hematologic cancer	3.25e-05	0.000106	CcSEcCtD
Salmeterol—Chest pain—Epirubicin—hematologic cancer	3.25e-05	0.000106	CcSEcCtD
Salmeterol—Arthralgia—Epirubicin—hematologic cancer	3.25e-05	0.000106	CcSEcCtD
Salmeterol—Myalgia—Epirubicin—hematologic cancer	3.25e-05	0.000106	CcSEcCtD
Salmeterol—Agitation—Doxorubicin—hematologic cancer	3.24e-05	0.000106	CcSEcCtD
Salmeterol—Anxiety—Epirubicin—hematologic cancer	3.24e-05	0.000106	CcSEcCtD
Salmeterol—Skin disorder—Methotrexate—hematologic cancer	3.23e-05	0.000105	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	3.22e-05	0.000105	CcSEcCtD
Salmeterol—Discomfort—Epirubicin—hematologic cancer	3.21e-05	0.000105	CcSEcCtD
Salmeterol—Vomiting—Triamcinolone—hematologic cancer	3.2e-05	0.000104	CcSEcCtD
Salmeterol—Malaise—Doxorubicin—hematologic cancer	3.18e-05	0.000104	CcSEcCtD
Salmeterol—Rash—Triamcinolone—hematologic cancer	3.18e-05	0.000104	CcSEcCtD
Salmeterol—Dry mouth—Epirubicin—hematologic cancer	3.17e-05	0.000104	CcSEcCtD
Salmeterol—Dermatitis—Triamcinolone—hematologic cancer	3.17e-05	0.000103	CcSEcCtD
Salmeterol—Urticaria—Prednisone—hematologic cancer	3.16e-05	0.000103	CcSEcCtD
Salmeterol—Headache—Triamcinolone—hematologic cancer	3.15e-05	0.000103	CcSEcCtD
Salmeterol—Body temperature increased—Prednisone—hematologic cancer	3.15e-05	0.000103	CcSEcCtD
Salmeterol—Abdominal pain—Prednisone—hematologic cancer	3.15e-05	0.000103	CcSEcCtD
Salmeterol—Diarrhoea—Dexamethasone—hematologic cancer	3.13e-05	0.000102	CcSEcCtD
Salmeterol—Diarrhoea—Betamethasone—hematologic cancer	3.13e-05	0.000102	CcSEcCtD
Salmeterol—Palpitations—Doxorubicin—hematologic cancer	3.12e-05	0.000102	CcSEcCtD
Salmeterol—Anaphylactic shock—Epirubicin—hematologic cancer	3.11e-05	0.000101	CcSEcCtD
Salmeterol—Oedema—Epirubicin—hematologic cancer	3.11e-05	0.000101	CcSEcCtD
Salmeterol—Infection—Epirubicin—hematologic cancer	3.09e-05	0.000101	CcSEcCtD
Salmeterol—Cough—Doxorubicin—hematologic cancer	3.08e-05	0.0001	CcSEcCtD
Salmeterol—Nervous system disorder—Epirubicin—hematologic cancer	3.05e-05	9.95e-05	CcSEcCtD
Salmeterol—Hypertension—Doxorubicin—hematologic cancer	3.05e-05	9.93e-05	CcSEcCtD
Salmeterol—Tachycardia—Epirubicin—hematologic cancer	3.04e-05	9.91e-05	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Methotrexate—hematologic cancer	3.03e-05	9.88e-05	CcSEcCtD
Salmeterol—Skin disorder—Epirubicin—hematologic cancer	3.02e-05	9.86e-05	CcSEcCtD
Salmeterol—Dizziness—Betamethasone—hematologic cancer	3.02e-05	9.85e-05	CcSEcCtD
Salmeterol—Dizziness—Dexamethasone—hematologic cancer	3.02e-05	9.85e-05	CcSEcCtD
Salmeterol—Insomnia—Methotrexate—hematologic cancer	3.01e-05	9.81e-05	CcSEcCtD
Salmeterol—Chest pain—Doxorubicin—hematologic cancer	3e-05	9.8e-05	CcSEcCtD
Salmeterol—Myalgia—Doxorubicin—hematologic cancer	3e-05	9.8e-05	CcSEcCtD
Salmeterol—Arthralgia—Doxorubicin—hematologic cancer	3e-05	9.8e-05	CcSEcCtD
Salmeterol—Anxiety—Doxorubicin—hematologic cancer	2.99e-05	9.76e-05	CcSEcCtD
Salmeterol—Nausea—Triamcinolone—hematologic cancer	2.99e-05	9.76e-05	CcSEcCtD
Salmeterol—Paraesthesia—Methotrexate—hematologic cancer	2.99e-05	9.74e-05	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	2.98e-05	9.73e-05	CcSEcCtD
Salmeterol—Discomfort—Doxorubicin—hematologic cancer	2.97e-05	9.68e-05	CcSEcCtD
Salmeterol—Dyspnoea—Methotrexate—hematologic cancer	2.96e-05	9.67e-05	CcSEcCtD
Salmeterol—Dry mouth—Doxorubicin—hematologic cancer	2.94e-05	9.58e-05	CcSEcCtD
Salmeterol—Hypersensitivity—Prednisone—hematologic cancer	2.93e-05	9.56e-05	CcSEcCtD
Salmeterol—Dyspepsia—Methotrexate—hematologic cancer	2.93e-05	9.55e-05	CcSEcCtD
Salmeterol—Vomiting—Betamethasone—hematologic cancer	2.91e-05	9.47e-05	CcSEcCtD
Salmeterol—Vomiting—Dexamethasone—hematologic cancer	2.91e-05	9.47e-05	CcSEcCtD
Salmeterol—Rash—Betamethasone—hematologic cancer	2.88e-05	9.4e-05	CcSEcCtD
Salmeterol—Rash—Dexamethasone—hematologic cancer	2.88e-05	9.4e-05	CcSEcCtD
Salmeterol—Oedema—Doxorubicin—hematologic cancer	2.88e-05	9.39e-05	CcSEcCtD
Salmeterol—Anaphylactic shock—Doxorubicin—hematologic cancer	2.88e-05	9.39e-05	CcSEcCtD
Salmeterol—Dermatitis—Dexamethasone—hematologic cancer	2.88e-05	9.39e-05	CcSEcCtD
Salmeterol—Dermatitis—Betamethasone—hematologic cancer	2.88e-05	9.39e-05	CcSEcCtD
Salmeterol—Fatigue—Methotrexate—hematologic cancer	2.87e-05	9.35e-05	CcSEcCtD
Salmeterol—Headache—Dexamethasone—hematologic cancer	2.86e-05	9.34e-05	CcSEcCtD
Salmeterol—Headache—Betamethasone—hematologic cancer	2.86e-05	9.34e-05	CcSEcCtD
Salmeterol—Infection—Doxorubicin—hematologic cancer	2.86e-05	9.33e-05	CcSEcCtD
Salmeterol—Asthenia—Prednisone—hematologic cancer	2.85e-05	9.31e-05	CcSEcCtD
Salmeterol—Pain—Methotrexate—hematologic cancer	2.84e-05	9.27e-05	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Epirubicin—hematologic cancer	2.84e-05	9.25e-05	CcSEcCtD
Salmeterol—Nervous system disorder—Doxorubicin—hematologic cancer	2.82e-05	9.21e-05	CcSEcCtD
Salmeterol—Insomnia—Epirubicin—hematologic cancer	2.81e-05	9.18e-05	CcSEcCtD
Salmeterol—Tachycardia—Doxorubicin—hematologic cancer	2.81e-05	9.17e-05	CcSEcCtD
Salmeterol—Skin disorder—Doxorubicin—hematologic cancer	2.8e-05	9.12e-05	CcSEcCtD
Salmeterol—Paraesthesia—Epirubicin—hematologic cancer	2.79e-05	9.11e-05	CcSEcCtD
Salmeterol—Dyspnoea—Epirubicin—hematologic cancer	2.77e-05	9.05e-05	CcSEcCtD
Salmeterol—Feeling abnormal—Methotrexate—hematologic cancer	2.74e-05	8.94e-05	CcSEcCtD
Salmeterol—Dyspepsia—Epirubicin—hematologic cancer	2.74e-05	8.93e-05	CcSEcCtD
Salmeterol—Diarrhoea—Prednisone—hematologic cancer	2.72e-05	8.88e-05	CcSEcCtD
Salmeterol—Gastrointestinal pain—Methotrexate—hematologic cancer	2.72e-05	8.87e-05	CcSEcCtD
Salmeterol—Nausea—Betamethasone—hematologic cancer	2.71e-05	8.85e-05	CcSEcCtD
Salmeterol—Nausea—Dexamethasone—hematologic cancer	2.71e-05	8.85e-05	CcSEcCtD
Salmeterol—Fatigue—Epirubicin—hematologic cancer	2.68e-05	8.75e-05	CcSEcCtD
Salmeterol—Pain—Epirubicin—hematologic cancer	2.66e-05	8.68e-05	CcSEcCtD
Salmeterol—Constipation—Epirubicin—hematologic cancer	2.66e-05	8.68e-05	CcSEcCtD
Salmeterol—Urticaria—Methotrexate—hematologic cancer	2.64e-05	8.62e-05	CcSEcCtD
Salmeterol—Dizziness—Prednisone—hematologic cancer	2.63e-05	8.58e-05	CcSEcCtD
Salmeterol—Abdominal pain—Methotrexate—hematologic cancer	2.63e-05	8.57e-05	CcSEcCtD
Salmeterol—Body temperature increased—Methotrexate—hematologic cancer	2.63e-05	8.57e-05	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	2.62e-05	8.56e-05	CcSEcCtD
Salmeterol—Insomnia—Doxorubicin—hematologic cancer	2.6e-05	8.49e-05	CcSEcCtD
Salmeterol—Paraesthesia—Doxorubicin—hematologic cancer	2.59e-05	8.43e-05	CcSEcCtD
Salmeterol—Dyspnoea—Doxorubicin—hematologic cancer	2.57e-05	8.37e-05	CcSEcCtD
Salmeterol—Feeling abnormal—Epirubicin—hematologic cancer	2.56e-05	8.36e-05	CcSEcCtD
Salmeterol—Gastrointestinal pain—Epirubicin—hematologic cancer	2.54e-05	8.3e-05	CcSEcCtD
Salmeterol—Dyspepsia—Doxorubicin—hematologic cancer	2.53e-05	8.27e-05	CcSEcCtD
Salmeterol—Vomiting—Prednisone—hematologic cancer	2.53e-05	8.25e-05	CcSEcCtD
Salmeterol—Rash—Prednisone—hematologic cancer	2.51e-05	8.18e-05	CcSEcCtD
Salmeterol—Dermatitis—Prednisone—hematologic cancer	2.51e-05	8.18e-05	CcSEcCtD
Salmeterol—Headache—Prednisone—hematologic cancer	2.49e-05	8.13e-05	CcSEcCtD
Salmeterol—Fatigue—Doxorubicin—hematologic cancer	2.48e-05	8.1e-05	CcSEcCtD
Salmeterol—Urticaria—Epirubicin—hematologic cancer	2.47e-05	8.06e-05	CcSEcCtD
Salmeterol—Pain—Doxorubicin—hematologic cancer	2.46e-05	8.03e-05	CcSEcCtD
Salmeterol—Constipation—Doxorubicin—hematologic cancer	2.46e-05	8.03e-05	CcSEcCtD
Salmeterol—Body temperature increased—Epirubicin—hematologic cancer	2.46e-05	8.02e-05	CcSEcCtD
Salmeterol—Abdominal pain—Epirubicin—hematologic cancer	2.46e-05	8.02e-05	CcSEcCtD
Salmeterol—Hypersensitivity—Methotrexate—hematologic cancer	2.45e-05	7.99e-05	CcSEcCtD
Salmeterol—Asthenia—Methotrexate—hematologic cancer	2.39e-05	7.78e-05	CcSEcCtD
Salmeterol—Feeling abnormal—Doxorubicin—hematologic cancer	2.37e-05	7.74e-05	CcSEcCtD
Salmeterol—Nausea—Prednisone—hematologic cancer	2.36e-05	7.71e-05	CcSEcCtD
Salmeterol—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.35e-05	7.68e-05	CcSEcCtD
Salmeterol—Hypersensitivity—Epirubicin—hematologic cancer	2.29e-05	7.48e-05	CcSEcCtD
Salmeterol—Urticaria—Doxorubicin—hematologic cancer	2.29e-05	7.46e-05	CcSEcCtD
Salmeterol—Abdominal pain—Doxorubicin—hematologic cancer	2.28e-05	7.42e-05	CcSEcCtD
Salmeterol—Body temperature increased—Doxorubicin—hematologic cancer	2.28e-05	7.42e-05	CcSEcCtD
Salmeterol—Diarrhoea—Methotrexate—hematologic cancer	2.28e-05	7.42e-05	CcSEcCtD
Salmeterol—Asthenia—Epirubicin—hematologic cancer	2.23e-05	7.28e-05	CcSEcCtD
Salmeterol—Dizziness—Methotrexate—hematologic cancer	2.2e-05	7.17e-05	CcSEcCtD
Salmeterol—Diarrhoea—Epirubicin—hematologic cancer	2.13e-05	6.94e-05	CcSEcCtD
Salmeterol—Hypersensitivity—Doxorubicin—hematologic cancer	2.12e-05	6.92e-05	CcSEcCtD
Salmeterol—Vomiting—Methotrexate—hematologic cancer	2.11e-05	6.9e-05	CcSEcCtD
Salmeterol—Rash—Methotrexate—hematologic cancer	2.1e-05	6.84e-05	CcSEcCtD
Salmeterol—Dermatitis—Methotrexate—hematologic cancer	2.09e-05	6.83e-05	CcSEcCtD
Salmeterol—Headache—Methotrexate—hematologic cancer	2.08e-05	6.79e-05	CcSEcCtD
Salmeterol—Asthenia—Doxorubicin—hematologic cancer	2.07e-05	6.74e-05	CcSEcCtD
Salmeterol—Dizziness—Epirubicin—hematologic cancer	2.06e-05	6.71e-05	CcSEcCtD
Salmeterol—Vomiting—Epirubicin—hematologic cancer	1.98e-05	6.45e-05	CcSEcCtD
Salmeterol—Nausea—Methotrexate—hematologic cancer	1.98e-05	6.44e-05	CcSEcCtD
Salmeterol—Diarrhoea—Doxorubicin—hematologic cancer	1.97e-05	6.43e-05	CcSEcCtD
Salmeterol—Rash—Epirubicin—hematologic cancer	1.96e-05	6.4e-05	CcSEcCtD
Salmeterol—Dermatitis—Epirubicin—hematologic cancer	1.96e-05	6.39e-05	CcSEcCtD
Salmeterol—Headache—Epirubicin—hematologic cancer	1.95e-05	6.36e-05	CcSEcCtD
Salmeterol—Dizziness—Doxorubicin—hematologic cancer	1.9e-05	6.21e-05	CcSEcCtD
Salmeterol—Nausea—Epirubicin—hematologic cancer	1.85e-05	6.03e-05	CcSEcCtD
Salmeterol—Vomiting—Doxorubicin—hematologic cancer	1.83e-05	5.97e-05	CcSEcCtD
Salmeterol—Rash—Doxorubicin—hematologic cancer	1.82e-05	5.92e-05	CcSEcCtD
Salmeterol—Dermatitis—Doxorubicin—hematologic cancer	1.81e-05	5.92e-05	CcSEcCtD
Salmeterol—Headache—Doxorubicin—hematologic cancer	1.8e-05	5.88e-05	CcSEcCtD
Salmeterol—Nausea—Doxorubicin—hematologic cancer	1.71e-05	5.58e-05	CcSEcCtD
Salmeterol—CYP3A5—Metabolism—ALOX5—hematologic cancer	1.07e-06	0.000489	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—IL2RA—hematologic cancer	1.07e-06	0.000486	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—IDH1—hematologic cancer	1.06e-06	0.000481	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PTGER4—hematologic cancer	1.06e-06	0.000481	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—LCK—hematologic cancer	1.05e-06	0.000479	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GSTO1—hematologic cancer	1.04e-06	0.000476	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—TXN—hematologic cancer	1.04e-06	0.000476	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ABCC3—hematologic cancer	1.04e-06	0.000476	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—NUP98—hematologic cancer	1.04e-06	0.000474	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—H3F3A—hematologic cancer	1.03e-06	0.000469	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HDC—hematologic cancer	1.02e-06	0.000466	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—SPHK1—hematologic cancer	1.02e-06	0.000465	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CYCS—hematologic cancer	1.02e-06	0.000463	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—HSP90AA1—hematologic cancer	1.01e-06	0.00046	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ADCY7—hematologic cancer	1.01e-06	0.00046	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—NCOA3—hematologic cancer	1.01e-06	0.00046	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—NUP214—hematologic cancer	1e-06	0.000457	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PRKCZ—hematologic cancer	1e-06	0.000456	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—MTR—hematologic cancer	9.82e-07	0.000448	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ABCG2—hematologic cancer	9.82e-07	0.000448	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—UGT1A1—hematologic cancer	9.81e-07	0.000447	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—PIK3CG—hematologic cancer	9.78e-07	0.000446	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PARP1—hematologic cancer	9.66e-07	0.00044	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ENO2—hematologic cancer	9.63e-07	0.000439	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—SLC22A1—hematologic cancer	9.54e-07	0.000435	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CRABP1—hematologic cancer	9.54e-07	0.000435	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—FBXW7—hematologic cancer	9.51e-07	0.000433	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CDA—hematologic cancer	9.35e-07	0.000426	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GSTT1—hematologic cancer	9.34e-07	0.000426	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CXCR4—hematologic cancer	9.32e-07	0.000425	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HDAC2—hematologic cancer	9.32e-07	0.000425	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ALOX5—hematologic cancer	9.3e-07	0.000424	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—SDC1—hematologic cancer	9.13e-07	0.000416	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CBL—hematologic cancer	9.08e-07	0.000414	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—NUP98—hematologic cancer	9.01e-07	0.000411	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PC—hematologic cancer	9e-07	0.00041	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IL3—hematologic cancer	8.99e-07	0.00041	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—GSTP1—hematologic cancer	8.96e-07	0.000408	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PIK3CG—hematologic cancer	8.88e-07	0.000405	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PTPN1—hematologic cancer	8.84e-07	0.000403	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ADCY7—hematologic cancer	8.74e-07	0.000399	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—NCOA3—hematologic cancer	8.74e-07	0.000399	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PTPN11—hematologic cancer	8.72e-07	0.000398	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—RASGRP1—hematologic cancer	8.69e-07	0.000396	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GBA—hematologic cancer	8.69e-07	0.000396	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SLC35B2—hematologic cancer	8.69e-07	0.000396	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—NUP214—hematologic cancer	8.68e-07	0.000396	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HSP90AA1—hematologic cancer	8.67e-07	0.000395	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—SYK—hematologic cancer	8.67e-07	0.000395	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—PIK3CD—hematologic cancer	8.6e-07	0.000392	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	8.59e-07	0.000392	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ABCG2—hematologic cancer	8.51e-07	0.000388	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—MTR—hematologic cancer	8.51e-07	0.000388	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ABCB1—hematologic cancer	8.48e-07	0.000387	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—CREB1—hematologic cancer	8.45e-07	0.000385	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—STAT1—hematologic cancer	8.36e-07	0.000381	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ENO2—hematologic cancer	8.34e-07	0.00038	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—CCL2—hematologic cancer	8.27e-07	0.000377	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—IL6R—hematologic cancer	8.25e-07	0.000376	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—NCOR1—hematologic cancer	8.23e-07	0.000375	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—GSTM1—hematologic cancer	8.23e-07	0.000375	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—PIK3R1—hematologic cancer	8.12e-07	0.00037	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GSTT1—hematologic cancer	8.09e-07	0.000369	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	7.97e-07	0.000363	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—MTAP—hematologic cancer	7.95e-07	0.000362	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—SDC1—hematologic cancer	7.91e-07	0.00036	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—JAK2—hematologic cancer	7.89e-07	0.00036	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—MAP2K1—hematologic cancer	7.86e-07	0.000358	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—GRB2—hematologic cancer	7.82e-07	0.000356	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PIK3CD—hematologic cancer	7.81e-07	0.000356	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PDGFA—hematologic cancer	7.8e-07	0.000356	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CD44—hematologic cancer	7.76e-07	0.000354	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—NQO1—hematologic cancer	7.76e-07	0.000354	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—KITLG—hematologic cancer	7.69e-07	0.00035	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	7.55e-07	0.000344	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—STAT5A—hematologic cancer	7.51e-07	0.000343	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—PIK3CB—hematologic cancer	7.49e-07	0.000342	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	7.46e-07	0.00034	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CDKN2B—hematologic cancer	7.45e-07	0.00034	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PIK3R1—hematologic cancer	7.37e-07	0.000336	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYCS—hematologic cancer	7.35e-07	0.000335	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—HSP90AA1—hematologic cancer	7.3e-07	0.000333	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—MTHFR—hematologic cancer	7.27e-07	0.000332	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CD86—hematologic cancer	7.2e-07	0.000328	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—JAK2—hematologic cancer	7.16e-07	0.000327	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	7.13e-07	0.000325	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HES1—hematologic cancer	7.11e-07	0.000324	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—FHL2—hematologic cancer	7.09e-07	0.000323	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NCOR1—hematologic cancer	7.06e-07	0.000322	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—FGF1—hematologic cancer	6.99e-07	0.000318	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CSF2—hematologic cancer	6.99e-07	0.000318	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—AGRN—hematologic cancer	6.95e-07	0.000317	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—FOXO1—hematologic cancer	6.88e-07	0.000314	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—IL2—hematologic cancer	6.88e-07	0.000314	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PDGFRB—hematologic cancer	6.87e-07	0.000313	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PIK3CB—hematologic cancer	6.8e-07	0.00031	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PDGFRA—hematologic cancer	6.77e-07	0.000308	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—JAK1—hematologic cancer	6.74e-07	0.000307	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PRKCG—hematologic cancer	6.74e-07	0.000307	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—NQO1—hematologic cancer	6.72e-07	0.000307	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CD44—hematologic cancer	6.72e-07	0.000307	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—IDH2—hematologic cancer	6.59e-07	0.0003	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HMMR—hematologic cancer	6.59e-07	0.0003	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	6.58e-07	0.0003	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GSTP1—hematologic cancer	6.47e-07	0.000295	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYCS—hematologic cancer	6.36e-07	0.00029	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—HSP90AA1—hematologic cancer	6.32e-07	0.000288	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IL2RA—hematologic cancer	6.3e-07	0.000287	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—IL2—hematologic cancer	6.25e-07	0.000285	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TERT—hematologic cancer	6.23e-07	0.000284	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ARNTL—hematologic cancer	6.19e-07	0.000282	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ABCB1—hematologic cancer	6.13e-07	0.000279	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PIK3CG—hematologic cancer	6.11e-07	0.000279	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PDGFB—hematologic cancer	6.08e-07	0.000277	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CA9—hematologic cancer	6.02e-07	0.000275	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ACP5—hematologic cancer	6.02e-07	0.000275	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—NCOR1—hematologic cancer	5.95e-07	0.000271	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GSTM1—hematologic cancer	5.95e-07	0.000271	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NCOR2—hematologic cancer	5.95e-07	0.000271	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TSC2—hematologic cancer	5.94e-07	0.000271	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—FGFR3—hematologic cancer	5.71e-07	0.00026	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	5.69e-07	0.000259	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CREBBP—hematologic cancer	5.67e-07	0.000258	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—IDH1—hematologic cancer	5.66e-07	0.000258	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MAPK14—hematologic cancer	5.66e-07	0.000258	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GSTP1—hematologic cancer	5.61e-07	0.000256	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTO1—hematologic cancer	5.6e-07	0.000255	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ABCC3—hematologic cancer	5.6e-07	0.000255	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—TXN—hematologic cancer	5.6e-07	0.000255	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ESR1—hematologic cancer	5.55e-07	0.000253	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—FN1—hematologic cancer	5.48e-07	0.00025	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SPHK1—hematologic cancer	5.48e-07	0.00025	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	5.43e-07	0.000247	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—BAD—hematologic cancer	5.42e-07	0.000247	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NFKBIA—hematologic cancer	5.42e-07	0.000247	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PIK3CD—hematologic cancer	5.37e-07	0.000245	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NOTCH1—hematologic cancer	5.36e-07	0.000245	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ABCB1—hematologic cancer	5.31e-07	0.000242	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ALB—hematologic cancer	5.3e-07	0.000242	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—UGT1A1—hematologic cancer	5.27e-07	0.00024	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—MTHFR—hematologic cancer	5.26e-07	0.00024	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CD80—hematologic cancer	5.26e-07	0.00024	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—KIT—hematologic cancer	5.25e-07	0.000239	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PIK3CG—hematologic cancer	5.25e-07	0.000239	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—NRAS—hematologic cancer	5.25e-07	0.000239	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GSTM1—hematologic cancer	5.15e-07	0.000235	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—NCOR1—hematologic cancer	5.15e-07	0.000235	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PTPN11—hematologic cancer	5.15e-07	0.000235	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CRABP1—hematologic cancer	5.12e-07	0.000234	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SLC22A1—hematologic cancer	5.12e-07	0.000234	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PIK3R1—hematologic cancer	5.07e-07	0.000231	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—MAPK3—hematologic cancer	5.02e-07	0.000229	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CREB1—hematologic cancer	4.99e-07	0.000228	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ALOX5—hematologic cancer	4.99e-07	0.000228	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—BRAF—hematologic cancer	4.93e-07	0.000225	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CCL2—hematologic cancer	4.89e-07	0.000223	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IL6R—hematologic cancer	4.87e-07	0.000222	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CREBBP—hematologic cancer	4.86e-07	0.000222	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NUP98—hematologic cancer	4.83e-07	0.00022	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ADCY7—hematologic cancer	4.69e-07	0.000214	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NCOA3—hematologic cancer	4.69e-07	0.000214	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PIK3CB—hematologic cancer	4.68e-07	0.000213	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NUP214—hematologic cancer	4.66e-07	0.000212	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MAP2K1—hematologic cancer	4.64e-07	0.000212	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PIK3CD—hematologic cancer	4.61e-07	0.00021	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—PIK3CA—hematologic cancer	4.57e-07	0.000208	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ABCG2—hematologic cancer	4.57e-07	0.000208	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—MTR—hematologic cancer	4.57e-07	0.000208	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—MTHFR—hematologic cancer	4.55e-07	0.000208	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—KRAS—hematologic cancer	4.51e-07	0.000206	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ENO2—hematologic cancer	4.48e-07	0.000204	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PIK3CG—hematologic cancer	4.42e-07	0.000201	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—FGF2—hematologic cancer	4.42e-07	0.000201	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PIK3R1—hematologic cancer	4.35e-07	0.000199	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTT1—hematologic cancer	4.34e-07	0.000198	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SDC1—hematologic cancer	4.24e-07	0.000193	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—JAK2—hematologic cancer	4.23e-07	0.000193	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PIK3CA—hematologic cancer	4.15e-07	0.000189	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MDM2—hematologic cancer	4.13e-07	0.000188	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CREBBP—hematologic cancer	4.1e-07	0.000187	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PTEN—hematologic cancer	4.05e-07	0.000184	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MTOR—hematologic cancer	4.02e-07	0.000183	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PIK3CB—hematologic cancer	4.02e-07	0.000183	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	4.01e-07	0.000183	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PIK3CD—hematologic cancer	3.88e-07	0.000177	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—EP300—hematologic cancer	3.86e-07	0.000176	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—HRAS—hematologic cancer	3.84e-07	0.000175	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ALB—hematologic cancer	3.83e-07	0.000175	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PIK3CG—hematologic cancer	3.83e-07	0.000174	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CDKN1B—hematologic cancer	3.77e-07	0.000172	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—AKT1—hematologic cancer	3.73e-07	0.00017	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CASP3—hematologic cancer	3.7e-07	0.000169	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IL2—hematologic cancer	3.69e-07	0.000168	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—IL6—hematologic cancer	3.67e-07	0.000167	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PIK3R1—hematologic cancer	3.67e-07	0.000167	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NQO1—hematologic cancer	3.61e-07	0.000165	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CD44—hematologic cancer	3.61e-07	0.000165	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CCND1—hematologic cancer	3.6e-07	0.000164	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—JUN—hematologic cancer	3.59e-07	0.000164	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CREBBP—hematologic cancer	3.55e-07	0.000162	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CDKN1A—hematologic cancer	3.48e-07	0.000159	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PTEN—hematologic cancer	3.47e-07	0.000158	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYCS—hematologic cancer	3.42e-07	0.000156	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MAPK8—hematologic cancer	3.4e-07	0.000155	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	3.39e-07	0.000155	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—AKT1—hematologic cancer	3.39e-07	0.000154	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PIK3CB—hematologic cancer	3.39e-07	0.000154	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PIK3CD—hematologic cancer	3.36e-07	0.000153	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ALB—hematologic cancer	3.32e-07	0.000151	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—EP300—hematologic cancer	3.31e-07	0.000151	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—SRC—hematologic cancer	3.22e-07	0.000147	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PIK3R1—hematologic cancer	3.18e-07	0.000145	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—VEGFA—hematologic cancer	3.14e-07	0.000143	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—STAT3—hematologic cancer	3.11e-07	0.000142	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NRAS—hematologic cancer	3.1e-07	0.000141	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTP1—hematologic cancer	3.01e-07	0.000137	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MAPK3—hematologic cancer	2.97e-07	0.000135	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PIK3CB—hematologic cancer	2.93e-07	0.000134	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PTEN—hematologic cancer	2.93e-07	0.000133	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MYC—hematologic cancer	2.89e-07	0.000132	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TGFB1—hematologic cancer	2.88e-07	0.000131	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PIK3CA—hematologic cancer	2.86e-07	0.00013	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ABCB1—hematologic cancer	2.85e-07	0.00013	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—EP300—hematologic cancer	2.79e-07	0.000127	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTM1—hematologic cancer	2.77e-07	0.000126	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NCOR1—hematologic cancer	2.77e-07	0.000126	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—KRAS—hematologic cancer	2.67e-07	0.000122	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PTEN—hematologic cancer	2.53e-07	0.000116	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PIK3CA—hematologic cancer	2.45e-07	0.000112	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—MTHFR—hematologic cancer	2.44e-07	0.000111	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—EP300—hematologic cancer	2.42e-07	0.00011	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TP53—hematologic cancer	2.37e-07	0.000108	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—AKT1—hematologic cancer	2.33e-07	0.000106	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HRAS—hematologic cancer	2.27e-07	0.000103	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IL6—hematologic cancer	2.17e-07	9.89e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PIK3CA—hematologic cancer	2.06e-07	9.41e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PIK3CG—hematologic cancer	2.05e-07	9.36e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—AKT1—hematologic cancer	2e-07	9.12e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CREBBP—hematologic cancer	1.9e-07	8.68e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PIK3CD—hematologic cancer	1.81e-07	8.23e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PIK3CA—hematologic cancer	1.79e-07	8.15e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ALB—hematologic cancer	1.78e-07	8.13e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.71e-07	7.77e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—AKT1—hematologic cancer	1.69e-07	7.69e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.57e-07	7.17e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—AKT1—hematologic cancer	1.46e-07	6.66e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PTEN—hematologic cancer	1.36e-07	6.2e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—EP300—hematologic cancer	1.3e-07	5.91e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PIK3CA—hematologic cancer	9.59e-08	4.37e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—AKT1—hematologic cancer	7.84e-08	3.57e-05	CbGpPWpGaD
